M&A / Deals Symeres and Ambagon collaborate for colorectal cancer molecules Pharmaceutical Business ReviewThe partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins.M&A / DealsOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Business Review The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins. M&A / DealsOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Telomir seeks FDA approval for Telomir-1 to treat breast cancerNext: Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
